Immunovant Reports Results of Batoclimab in P-II Trial for the Treatment of Graves’ Disease
Shots:
- The P-II trial evaluates the safety & efficacy of batoclimab in patients with Graves’ Disease who are hyperthyroid despite treatment with an anti-thyroid medication (ATD). The enrolled patients initially received 680mg (SC, qw) of batoclimab for 12wks. followed by 340mg (SC, qw) for 12wks.
- As per the results, IgG reduction in patients receiving 680mg dosage was up to 87% with a mean reduction of 81% after 12wks. whereas reduction with 340mg was lower. Moreover, deeper reductions were observed in anti-TSHR autoantibodies with 680mg of batoclimab vs 340mg
- Additionally, in clinical parameters, incl. the percentage of patients whose ATD dose was reduced & whose ATD was discontinued, higher responses were observed with 680mg vs 340mg
Ref: Immunovant | Image: Immunovant
Related Post:- Cullinan Oncology Entered into an Exclusive License with Harbour BioMed to Develop and Commercialize HBM7008 (CLN-418) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
